Possibilities for the use of anakinra in COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-60-63
Abstract
The use of anakinra cannot be currently recommended outside of clinical trials as pathogenetic treatment of “cytokine storm” in severe COVID-19.
About the Authors
V. A. Otdelenov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770
Moscow
A. V. Matveev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. KINERET ® (anakinra) injection, for subcutaneous use. FULL PRESCRIBING INFORMATION [Internet]. [cited 2020 May 25]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103950s5182lbl.pdf
2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. DOI: 10.1007/s00281-017-0629-x
3. Wong CK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. DOI: 10.1111/j.1365-2249.2004.02415.x
4. Gong J et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. MedRxiv. 2020 February 27. DOI: 10.1101/2020.02.25.20025643.
5. Temporary guidelines of the Ministry of health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (28.04.2020). (In Russ). Доступно по: https://clck.ru/NCM6x Ссылка активна на 25.05.2020
6. UW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. [cited 2020 May 25]; Available from: https://covid-19.uwmedicine.org/Pages/default.aspx
7. Colleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Internet]. 2020. P. Guidelines. [cited 2020 May 25]; Available from: https://covid19evidence.net.au/
8. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2020 May 25]; Available from: https://www.covid19treatmentguidelines.nih.gov/
9. Brigham and Women’s Hospital COVID-19 Clinical Guidelines Therapeutics — Anti-IL-1 Agents (Anakinra, Canakinumab, Rilonacept) [Internet]. [cited 2020 May 22]; Available from: https://covidprotocols.org/protocols/therapeutics/#anti-il-1-agents-anakinra-canakinumab-rilonacept
10. Filocamo G et al. Use of anakinra in severe COVID-19: a case report. Int J Infect Dis. 2020 Jul;96:607-609. DOI: 10.1016/j.ijid.2020.05.026
11. Franzetti M et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int J Infect Dis. 2020 Aug;97:215-218. DOI: 10.1016/j.ijid.2020.05.050
12. Lopalco G et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. Italy, 2016. Vol. 34, No 3. P. 531- 538.
13. Explanations of the Ministry of health of the Russian Federation dated October 30, 2018 About importation to the Russian Federation of the specific party of the unregistered medicines intended for rendering medical care on vital indications of the specific patient. (In Russ). Доступно по: https://www.garant.ru/products/ipo/prime/doc/71995356/ Ссылка активна на 27.05.2020
Review
For citations:
Otdelenov V.A., Matveev A.V., Sychev D.A. Possibilities for the use of anakinra in COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):60-63. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-60-63
Views:
4321
Email this article 